Bayer advances innovations to benefit patients

At the event the company presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovative healthcare solutions for the benefits of patients and delivering long-term, sustainable business growth. Christian Rommel, member of the executive committee of the pharmaceuticals division and head of R&D, said: “Patient needs, precision therapies to address disease complexity as well as advances in science and technology are evolving rapidly. With recent major investments, including tin and the acquisition of Vividion Therapeutics, Bayer has fortified its oncology innovation engine substantially. “Bayer has clear ambitions to become a top oncology company. Bayer works on leveraging all the possibilities of the technologies while fully integrating all regulatory and bioethical requirements.